Atara Biotherapeutics, Inc.

Atara Biotherapeutics is a leading allogeneic T-cell immunotherapy company pioneering the development of transformative off-the-shelf therapies for patients with serious diseases including cancer, autoimmune conditions, and viral diseases. The company is the first to receive regulatory approval of an allogeneic T-cell immunotherapy. Atara's proprietary EBV T-cell platform uses naturally occurring biology without requiring T-cell receptor or HLA gene editing, forming the basis of a diverse pipeline. The company develops both EBV-specific T-cell therapies and next-generation allogeneic CAR-T (AlloCAR-T) technologies for broader applications in hematologic malignancies and B-cell driven autoimmune diseases. With manufacturing capabilities in California, Atara is positioned as a key player in the emerging off-the-shelf cell therapy market.